Prostate Cancer Market Set to Grow at an 8.1% CAGR Through 2030 as PARP Inhibitors and Next-Gen Hormonal Therapies Reshape the Treatment Landscape

DelveInsight's, "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate Cancer, historical and forecasted epidemiology, as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Download DelveInsight's comprehensive Prostate Cancer Market Report to explore emerging therapies, key players, and future treatment landscapes @ https://www.delveinsight.com/report-store/prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Prostate Cancer Market Report
• Prostate Cancer Market size is expected to increase at a CAGR of 8.1% for the study period 2017-2030, with the US anticipated to occupy the most substantial chunk of the market by 2030.
• The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 in 2017, with prevalence in the 7MM expected to reach 7,494,882 by 2020.
• In March 2025, Quibim announced that its QP-Prostate® CAD solution for prostate cancer lesion detection received FDA 510(k) clearance.
• In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
• In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
• On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.
• The leading Prostate Cancer Companies include AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Candel Therapeutics, Merck Sharp & Dohme, and others.
• Promising Prostate Cancer Therapies such as Lynparza (olaparib), Rucaparib, Opdivo (nivolumab), 177Lu-PSMA-617, Talazoparib, ProstAtak, Relugolix, Capivasertib, and others.

Access DelveInsight's in-depth Prostate Cancer Market Analysis for a closer look at promising breakthroughs @ https://www.delveinsight.com/report-store/prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Prostate Cancer Market Report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size from 2017 to 2030 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Prostate Cancer Overview
Prostate Cancer is a type of malignancy that occurs in the prostate gland, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is one of the most common types of cancer found in men, usually growing slowly and confined to the prostate gland initially. More than 99% of prostate cancers are adenocarcinomas, and the disease is common in men aged 50-64 and over 65, though it can occur in younger men. Symptoms include blood in the semen, frequent urge to urinate, and painful urination, though these typically do not appear until the prostate is large enough to affect the urinary tract. Clinical stage and treatment pattern are key factors, with patients classified as hormone-sensitive (HSPC/CSPC) or, following failure to respond to ADT, castrate-resistant (CRPC).

Prostate Cancer Emerging Drugs Profile

Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme
Lynparza is a first- and best-in-class oral poly ADP-ribose polymerase (PARP) inhibitor, the first targeted treatment to block DDR in tumors harboring a deficiency in homologous recombination repair, such as BRCA1/BRCA2 mutations. It is being developed for metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic HRR gene mutations, based on results from the Phase III PROfound trial. Currently, the drug is in the pre-registration stage of development.

177Lu-PSMA-617: Novartis
177Lu-PSMA-617 is an investigational radioligand therapy (RLT) in development for mCRPC. Currently, the drug is in the Phase III VISION trial for the treatment of patients with progressive PSMA-positive mCRPC.

Explore groundbreaking therapies and clinical trials in the Prostate Cancer Market. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/report-store/prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Prostate Cancer Market Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer, with aggregate therapies developed by each company for the same.
• It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Prostate Cancer treatment.
• Prostate Cancer Companies are involved in targeted therapeutics development with respective active pipeline projects across PARP inhibitors, androgen receptor inhibitors, immunotherapies, and radioligand therapies.
• Prostate Cancer Drugs under development are assessed based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Prostate Cancer Market.

Prostate Cancer Companies
AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Candel Therapeutics, Merck Sharp & Dohme, and others.

Prostate Cancer Market Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Prostate Cancer Products have been categorized under various Molecule types such as
• Small molecule
• Monoclonal antibody
• Radioligand therapy
• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ https://www.delveinsight.com/report-store/prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Prostate Cancer Market Report
• Coverage- 7MM (US, EU5, Japan)
• Study Period- 2017-2030
• Prostate Cancer Companies- AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Candel Therapeutics, Merck Sharp & Dohme, and others.
• Prostate Cancer Therapies- Lynparza (olaparib), Rucaparib, Opdivo (nivolumab), 177Lu-PSMA-617, Niraparib ± Abiraterone Acetate, HC-1119, Ipatasertib (RG7440), Talazoparib, ProstAtak, Relugolix, Capivasertib, Seviteronel, PRX302 (topsalysin), RV001, and others.
• Prostate Cancer Market CAGR (2017-2030)- 8.1%
• Prostate Cancer Therapeutic Assessment by Clinical Stages- Pre-registration, Phase III, Phase II

Find out in DelveInsight's exclusive Prostate Cancer Market Report-access it now! @ https://www.delveinsight.com/report-store/prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Prostate Cancer: Disease Understanding and Treatment Algorithm
4. Prostate Cancer Epidemiology
5. Prostate Cancer Current Treatment Practices
6. Prostate Cancer Marketed Drugs
7. Xtandi (Enzalutamide): Astellas Pharma/Pfizer
8. Erleada (apalutamide): Janssen Pharmaceutical
9. Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation
10. Prostate Cancer Emerging Drugs
11. Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme
12. 177Lu-PSMA-617: Novartis
13. Prostate Cancer Pipeline Development Activities
14. Prostate Cancer Market Outlook and Drugs Uptake
15. Reimbursement Scenario in Prostate Cancer
16. KOL Views
17. Prostate Cancer Competitive Intelligence Analysis
18. Prostate Cancer Market Size and Forecast (2017-2030)
19. Prostate Cancer Key Companies
20. Appendix
21. About Us

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.